GC
GKOS
HealthcareGlaukos Corp.
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
6
ProductBullishPer-CompanyMar 20, 2026
Glaukos Launches Epioxa, First FDA-Approved Topical Treatment for Keratoconus
- ▸Epioxa launched as first FDA-approved, incision-free topical drug for keratoconus
- ▸Eliminates need for corneal epithelium removal required in traditional cross-linking
- ▸Targets large, underpenetrated market with non-invasive, patient-friendly alternative
- ▸Company investing in awareness campaigns and screening to drive procedure volumes
- ▸GKOS market capitalization currently stands at $5.9 billion
8
EarningsBearishPer-CompanyMar 19, 2026
Glaukos Q4 revenue $143.1M beats estimates by 6%, raises 2026 revenue guidance
- ▸Q4 revenue $143.1M, +36% YoY, beating estimates by 6%
- ▸Q4 adjusted loss of $0.28/share missed estimates of $0.22/share
- ▸Glaucoma segment sales $119.2M, up 42% YoY
- ▸Raised 2026 revenue guidance to $600M–$620M range
- ▸Adjusted gross margin expanded to 85.1% from 82.3% YoY